Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors

NCT05217693 is registered in ClinicalTrials.gov with Bliss Biopharmaceutical (Hangzhou) Co., Ltd as lead sponsor.

NCT NCT05217693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05217693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2022
Completion date
December 31, 2025
Enrollment
288 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor